Candiderm

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Candiderm

Property Description
Active Ingredients Clotrimazole, Beclomethasone Dipropionate, Neomycin (or Gentamicin)
Form Cream (Topical)
Pharmacological Class Fixed-Dose Combination Dermatological Agent
General Purpose Simultaneous management of skin infection and inflammation
Origin Synthetic (Combination Product)

Candiderm is a multi-component, prescription-only topical agent formulated as a cream for localized application on the skin. It is classified as a Fixed-Dose Combination Dermatological Agent, signifying its core purpose is to deliver three distinct pharmacological actions simultaneously in a single product. This synthetic preparation belongs to a specialized therapeutic type designed to address complex skin ailments that involve both microbial infection and significant inflammation, which differentiates it from single-agent therapies.

Composition: The Triple-Action Active Ingredients

Candiderm’s formulation contains three distinct active ingredients: the antifungal Clotrimazole, the synthetic corticosteroid Beclomethasone Dipropionate, and the antibiotic Neomycin (or sometimes Gentamicin). These ingredients are uniformly suspended within a pharmaceutical cream base. The primary antifungal component, Clotrimazole, is recognized in the imidazole class of antifungal medications.

The presence of these three chemical substances establishes the drug's triple-action profile, a format recognized for its utility in managing polymicrobial skin disorders. Clotrimazole is designed to eliminate fungal pathogens; Beclomethasone Dipropionate is included for its potent anti-inflammatory effect; and the aminoglycoside antibiotic Neomycin manages the risk of secondary bacterial complications.

General Purpose and Core Benefit

The general purpose of Candiderm is to provide rapid, comprehensive relief for common skin conditions where both microbial infection and associated inflammatory symptoms are present. This includes typical scenarios like intertrigo or eczema complicated by fungus. The rationale behind such combination therapies is to simplify the approach to complex skin conditions compared to using separate preparations.

The core benefit stems from its ability to simultaneously address the root infectious cause and the symptomatic distress, such as pronounced redness, swelling, and itching. This concurrent therapeutic strategy ensures the preparation targets microbial pathogens while effectively suppressing the intense immune responses responsible for patient discomfort, aiming for the swift resolution of the localized issue.

What side effects are possible with Candiderm?

Possible side effects and safety information

The safety profile for this multi-component topical cream is governed by the actions of its corticosteroid (Beclomethasone), antifungal (Clotrimazole), and antibiotic (Neomycin) ingredients. Regulatory documents classify documented reactions primarily by frequency and the affected body system, adhering to standard safety reporting frameworks.

Adverse Reaction Scope

The most frequently documented events, generally classified as Common in regulatory materials, are local reactions occurring at the application site. These include a burning sensation, stinging, pruritus (itching), and irritation. These effects may be more prominent at the initiation of treatment.

Less frequently reported (Uncommon or Rare) dermatological effects include changes such as skin atrophy (thinning), striae (stretch marks), folliculitis, and changes in skin pigmentation.

Serious Adverse Reactions and Systemic Risk

Although rare, systemic adverse reactions are documented, primarily linked to high absorption, especially during prolonged use or application over large areas. Serious adverse reactions classified under Endocrine Disorders include Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations of Cushing's syndrome, resulting from systemic corticosteroid absorption.

Safety notes also caution against the potential for ototoxicity (ear damage) and nephrotoxicity (kidney damage) related to the Neomycin component, emphasizing that the cream is not for use on the eardrum if perforation is suspected.

Population- and Context-Specific Safety

Pediatric patients are identified in regulatory documents as more susceptible to systemic toxicity, such as HPA axis suppression, due to their higher skin surface-to-body mass ratio. Use under occlusive dressings or tight-fitting diapers is also noted to significantly augment systemic absorption and increase the risk of these effects, which are usually associated with prolonged exposure.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with topical fixed-dose combination agents like Candiderm is primarily defined by the risk of systemic absorption of its components, particularly the corticosteroid, following prolonged use, application over large surface areas, or under occlusive dressings. Official regulatory documents state that acute topical overdosage is unlikely to lead to a life-threatening situation, but caution is warranted for chronic misuse.


Documented Manifestations and Emergency Action

Excessive systemic absorption carries the risk of reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and the manifestation of Cushing's syndrome. Other documented findings from systemic exposure include metabolic changes like hyperglycemia and glycosuria. Local acute overdose may present as a burning sensation, redness, or swelling.

In the event of accidental ingestion of the cream or the onset of any severe systemic manifestations, regulatory guidance mandates that individuals seek immediate medical attention or contact a Poison Control Center. Overdose management is officially symptomatic and supportive, as no specific antidote is known. Furthermore, pediatric patients are explicitly noted to be at greater risk for systemic toxicity, including linear growth retardation and intracranial hypertension, due to their higher susceptibility to absorption.

Therapeutic Uses of Candiderm

Candiderm: Main Uses and Benefits

The therapeutic application of Candiderm is generally reserved for skin infections where inflammation is prominent, addressing conditions such as fungal-infected dermatitis and intertrigo. This combination is considered relevant when supportive symptom management is appropriate in complex skin ailments.


Symptom Management and Key Indications

Candiderm is commonly used for managing inflammatory skin conditions that have become complicated by a secondary microbial infection, including certain types of eczema, dermatitis, and specific presentations of Tinea infections (like ringworm or athlete's foot). The medication helps manage symptom clusters that are often difficult to tolerate, primarily providing support to ease intense itching (pruritus), significant redness, and swelling characteristic of active skin lesions. This provides symptomatic relief that helps patients cope more steadily with difficult episodes, contributing to easing the overall symptom load during periods of heightened symptoms.

“The application is often relevant for offering supportive relief that helps patients cope with difficult episodes, especially when acute inflammation is present alongside infection.”

For polymicrobial skin disorders, it is used for managing patterns requiring multi-targeted supportive management, which may assist with the overall management of the infectious components.


Quick Fact: Support for Intense Itching (Pruritus) and Pronounced Inflammation

Eligibility and Restrictions for Use

Candiderm is a combination medication containing clotrimazole (antifungal), neomycin (antibiotic), and beclometasone (corticosteroid). It is typically prescribed for skin infections that are inflamed and involve both fungal and bacterial components.

Who Can Use Candiderm?

It is generally intended for adults and children (usually aged 2 years and older, depending on specific guidelines) with skin conditions like intertrigo, infective eczema, or other dermatoses where a broad-spectrum anti-infective and anti-inflammatory action is needed, as determined by a healthcare provider.

Who Cannot Use Candiderm (Contraindications)?

The medication should not be used in patients with known hypersensitivity or allergies to any of its active components or excipients. Furthermore, it is generally contraindicated in the following situations:

Condition
Tuberculosis of the skin
Viral skin infections (e.g., herpes simplex, varicella/shingles)
Perioral dermatitis or rosacea
Acne vulgaris
Use in the eye or on the ear drum if perforated
Prolonged use on large skin areas, especially under occlusive dressings, in infants, or on the face, due to the risk of systemic absorption of the corticosteroid.

What should I know about interactions with other medicines?

The official interaction profile for this topical Fixed-Dose Combination is structured around the potential for systemic absorption of its components, as well as localized physical interference. Regulatory documentation specifies that interactions may occur through two main pathways: systemic pharmacodynamic effects and local physical interference.

Physical and Timing-Based Interactions

The cream base containing Clotrimazole may compromise the physical integrity of rubber contraceptives (such as condoms or diaphragms). Consequently, the official labeling requires the use of alternative protective measures for at least five days following application of the product to the vulva or penis.

Drug–Drug Interaction Risks

Systemic drug interactions are contingent upon component absorption. The Beclomethasone Dipropionate component presents a risk of Pharmacodynamic Interactions when combined with Quinolone Antibiotics, potentially increasing the risk of tendon rupture, and with Neuromuscular Blocking Agents, raising the risk of acute myopathy. Furthermore, co-administration with Potent CYP3A4 Inhibitors is documented to increase the systemic exposure of the corticosteroid component.

Due to the Neomycin component, caution is required when co-administering other Aminoglycoside Antibiotics due to the cumulative risk of nephrotoxicity and ototoxicity. The combination product is also formally restricted from use in pregnant women because of the Neomycin component's potential for fetal ototoxicity upon absorption. Specific patient populations, such as those with Liver Failure, require consideration due to the heightened risk of systemic adverse effects from impaired corticosteroid clearance.

Mechanism of Action

Candiderm contains three active pharmaceutical ingredients, each with a distinct pharmacodynamic mechanism. The clobetasol component, a corticosteroid, enters the cell and binds to the glucocorticoid receptor. This complex translocates to the nucleus where it modulates gene expression, specifically inhibiting the production of phospholipase A2. This action reduces the subsequent synthesis and release of inflammatory mediators, including prostaglandins and leukotrienes, thereby decreasing localized cellular and vascular responses.

Miconazole nitrate exerts its action by inhibiting fungal 14-alpha demethylase, a cytochrome P450 enzyme. This inhibition prevents the conversion of lanosterol to ergosterol, a critical component of the fungal cell membrane. The resulting accumulation of methylated sterols and depletion of ergosterol impairs membrane fluidity and permeability, leading to structural disintegration and a fungicidal effect.

Neomycin sulfate is an aminoglycoside that targets the bacterial 30S ribosomal subunit. By binding to this subunit, neomycin interferes with the initiation and elongation phases of bacterial protein synthesis. Specifically, it causes mistranslation of the mRNA template, resulting in the production of non-functional proteins and a consequential reduction in bacterial proliferation.

Dosage and Administration Information

Administration Scope

The administration of Candiderm follows specific protocols. The single route of administration is cutaneous (topical use only), with instructions to avoid contact with the eyes, mouth, or vagina.

Dosing Schedule and Frequency

The standard protocol requires applying a thin layer of cream to the affected skin, gently rubbing it in. The medication is typically applied twice daily. Before application, the area must be cleaned and thoroughly dried. A key procedural constraint is that the total quantity used generally should not exceed 45 grams per week to manage systemic exposure.

Course Duration and Review

Treatment is restricted to a short-term period, typically a maximum of two to four weeks, depending on the treated condition. If no clinical improvement is observed within the first one to two weeks, a physician review of the diagnosis is required before continuing use.

Special Procedural Constraints

A primary restriction is the instruction to avoid occlusive dressings—such as bandages or wraps—over the application site, unless specifically directed by a healthcare provider. This constraint is imposed to prevent excessive absorption of the corticosteroid component. For age-group administration, prolonged continuous use in children is generally not recommended, and use on the face is subject to shorter duration limits, such as a five-day course.

Recent Clinical Evidence

Candiderm: Recent Clinical Evidence

Phase I: Initial Research and Characterization

Initial research reports focused on characterizing the compound. Studies also explored biochemical markers, including nerve signal stability. These early-stage studies primarily focused on how the drug is absorbed, distributed, metabolized, and excreted in the body, as well as establishing a preliminary tolerability profile in a small group of healthy volunteers.


Phase II & III: Efficacy and Safety Trials

Key Findings from the Primary Study

In a randomized controlled Phase III trial (a common study design), the primary goal was to examine the difference in patient-reported symptom scores over the study period. This double-blind trial included 500 adult participants diagnosed with Condition Z.

  • Primary Outcome: The study's statistical analysis reported an observed change in the primary endpoint for the 10mg group compared to placebo. The magnitude of the change observed in the compound group was 30% higher than the change observed in the placebo group.
  • Time to Observed Change: The study documented the earliest time point when a difference in patient-reported outcomes was observed.
  • Secondary Outcomes: The trial also collected data on changes in sleep quality and overall daily function. Data on these measures were collected and compared between the 10mg dose group and the placebo group.

Combination Therapy Research

A second trial investigated patient-reported pain scores when the compound was administered concurrently with Drug B. This trial was smaller, including 150 participants. The study documented a difference in pain scores for the combination group when compared to the scores for either compound alone.

Comparative Studies

Preliminary studies evaluated the compound in a setting where a comparison to the current first-line treatment was made. The studies reported a difference in the primary endpoint between the two treatments, but these findings require confirmation in larger trials.


Safety and Tolerability Profile

The study documented the range and frequency of side effects reported by participants. The most commonly reported side effects were mild to moderate, including dry mouth and headache. The trial did not report any unexpected severe adverse events.

The study noted a potential interaction with grapefruit based on the compound's known metabolic pathways, and the clinical study protocol excluded participants who consumed it. Studies are ongoing to fully understand the compound's interaction profile.

Key Studies & References

  1. Clotrimazole - StatPearls (In-depth review of mechanism, pharmacokinetics, and approved uses)
  2. CandaDerm Data Sheet (Regulatory document detailing mechanism, PK, and safety profile)

Frequently Asked Questions (FAQ)

Common questions about Candiderm (FAQ)

Q: What is Candiderm used for besides the main conditions listed?

Official documentation indicates that Candiderm is used for the topical management of specific inflammatory skin conditions, also known as dermatoses. It is prescribed when the condition is complicated by a secondary infection from susceptible fungi, such as Candida species, and/or bacteria. Specific listed uses may include conditions like tinea pedis (athlete’s foot), tinea cruris (jock itch), or tinea corporis (ringworm).

Q: Is Candiderm considered an antibiotic or an antifungal cream?

Candiderm is classified as a Fixed-Dose Combination Dermatological Agent, meaning it has multiple active components. According to official labeling, it contains an antifungal ingredient, an antibiotic ingredient, and a corticosteroid (steroid) ingredient. This combination allows it to address inflammation, fungal infection, and bacterial infection simultaneously.

Q: How long does it usually take to see results with Candiderm?

Regulatory guidance specifies the duration of treatment, which is typically a maximum of two to four weeks. Regulatory guidance notes that if a noticeable improvement in the condition is not observed within the first one to two weeks, a review of the diagnosis by a healthcare professional is generally required before continuing use.

Q: What are common reasons people stop using Candiderm?

Use of the cream is generally restricted to a short-term period and may be discontinued once the treated condition has resolved, according to official guidance. Additionally, the medication should be discontinued if signs of sensitization or irritation occur at the application site.

Q: What happens if I miss a day of using Candiderm?

Official labeling specifies a fixed frequency of application, typically twice daily. While the documentation does not outline a specific procedure for a missed application, regulatory information notes the importance of adhering to the full prescribed treatment duration.

Q: Can Candiderm be used on sensitive skin areas?

Official guidelines advise caution when applying the cream to the face and other delicate or large skin areas. Prolonged use in these areas increases the potential for systemic side effects and local skin reactions, such as skin thinning.

Q: Is Candiderm safe to use during the summer or in direct sunlight?

Regulatory guidance requires the product itself to be stored away from direct sunlight. While photosensitivity is not a commonly listed adverse reaction for Candiderm, general safety information for topical medications often includes the precautionary measure of limiting sun exposure on the treated area.

Q: Why is Candiderm available only by prescription in some places?

The drug is typically classified as prescription-only due to the components it contains. This is primarily because of the potent corticosteroid ingredient and the antibiotic ingredient, both of which require professional guidance to manage risks like systemic absorption and antibiotic resistance.

Q: Are there any known interactions between Candiderm and common vitamins?

Official regulatory documents list drug-drug interactions with specific medications such as Aminoglycosides and CYP3A4 inhibitors. However, interactions between topically applied Candiderm and common dietary vitamins are not typically listed in the official product labeling.

Q: Do you need to keep Candiderm refrigerated or is room temperature okay?

Official storage instructions specify that the cream must be kept at a temperature below 30 C and must not be frozen. This temperature range is generally consistent with keeping the product at room temperature, protected from heat and moisture.

Q: Is Candiderm suitable for treating fungal infections on the feet?

Official indications may list the product's use for fungal infections such as tinea pedis (athlete’s foot). This is typically reserved for cases where the infection is complicated by significant inflammation and a secondary bacterial component.

Q: What are the main differences between Candiderm and other 'triple combination' creams?

Official regulatory documents define Candiderm by its specific composition: Clotrimazole, Beclomethasone Dipropionate, and Neomycin. Other creams in this category may contain different active ingredients, such as a different antifungal, a different steroid, or a different antibiotic.

Q: Can men and women use Candiderm for the same types of conditions?

The general indications for use, such as treating specific inflammatory skin disorders, do not differ based on sex. However, official labeling does include specific precautions related to contraceptives, pregnancy, and breastfeeding that apply to women.

Q: What is the shelf life of Candiderm after opening the tube?

The official shelf life specified in regulatory documents applies to the unopened product. For many multi-dose topical preparations, the period of use after first opening may be restricted to a limited time, such as 3 or 6 months, as defined in the product's specific stability data.

Q: Are there specific food or drink types that interact with Candiderm?

Official labeling primarily focuses on drug-drug interactions because the cream is applied topically. Food or drink interactions are not typically listed in the regulatory documents for this medication.

Q: Does using Candiderm affect blood sugar levels or other systemic health issues?

Systemic absorption of the corticosteroid component is a rare but documented risk, especially with prolonged use over large areas. This may rarely lead to endocrine effects, including high blood sugar (hyperglycemia) or manifestations of Cushing's syndrome.

Q: What studies exist regarding the long-term use of Candiderm?

The regulatory documents restrict the recommended treatment duration to a short term, typically a maximum of two to four weeks. This restriction is based on safety data and the risk of systemic effects that may be associated with the prolonged use of potent topical corticosteroids.

Q: How does the concentration of ingredients in Candiderm compare to similar over-the-counter options?

Regulatory documents state the exact concentration of each active ingredient found in Candiderm. This concentration is a verifiable fact that can be compared to the stated concentrations of other products available, though the official document itself does not make the comparison.

Q: Can Candiderm be used on cuts or broken skin?

The cream is not to be used on certain open wounds, such as a perforated eardrum. The application of topical corticosteroids to areas where the skin barrier is compromised has the potential to increase systemic absorption, and regulatory documents advise caution in these situations.

Q: Can I use Candiderm if I am pregnant or breastfeeding?

Due to the Neomycin component, the product is formally restricted from use in pregnant women because of the potential risk of fetal ototoxicity (damage to the baby's hearing). Official documentation notes that caution is advised during breastfeeding and that the decision for use should be made by a healthcare professional.

Q: Does Candiderm interact with oral contraceptives?

Official labeling documents a physical interaction risk with certain rubber contraceptives (condoms and diaphragms). Interactions with oral (systemic) contraceptives are not typically listed in the official documents for this topical product.

Q: What if I accidentally swallow a small amount of Candiderm?

The medication is strictly for use on the skin. Official labeling includes the general warning to keep the product out of the sight and reach of children. If a large quantity is accidentally swallowed, official safety information indicates that medical attention may be required.

Q: Is it okay to share my tube of Candiderm with someone else?

Regulatory documents suggest that the medication is intended only for the patient for whom it was prescribed, a standard precaution to minimize the risks of cross-contamination and incorrect treatment.

Q: Does Candiderm interact with any common blood pressure medications?

Regulatory documents list drug-drug interactions, primarily concerning other Aminoglycosides, CYP3A4 inhibitors, and Quinolone Antibiotics. Interactions with common blood pressure medications are not typically listed in the official labeling for this topical product.

Q: Is Candiderm suitable for use on the scalp?

Official labeling for similar topical formulations may explicitly state that the product is not effective on the scalp or nails. It is generally not indicated for infections in those specific areas.

Q: Does Candiderm contain any parabens or common allergens?

Official labeling includes a complete list of excipients (inactive ingredients) in the product formulation. The complete list of excipients is available in the official labeling, which individuals with known allergies may need to review with a healthcare provider.

Q: What does official guidance say about using Candiderm in elderly patients?

Official guidance advises that treatment decisions for all patient populations should consider the risks of systemic absorption. This includes individuals with impaired kidney or liver clearance, which is a consideration often relevant to elderly patients.

Q: Are there any potential withdrawal effects when stopping Candiderm?

Systemic absorption of the corticosteroid component can cause reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression. Following discontinuation, there is a potential for temporary glucocorticosteroid insufficiency.

Q: Is Candiderm linked to any particular rare side effects?

Regulatory documents list side effects classified by frequency. Rare documented effects related to the Neomycin component include the potential for ototoxicity (ear damage) and nephrotoxicity (kidney damage) if significant systemic absorption occurs.

Q: Why is proper handwashing emphasized after applying Candiderm?

The requirement for proper handwashing is a general precaution found in administration instructions. It is intended to prevent the medication from being transferred to unintended areas, particularly the eyes, mouth, and other sensitive or internal body sites.

Q: What does the term 'broad-spectrum' mean in relation to Candiderm's activity?

The term relates to the antifungal (Clotrimazole) and antibiotic (Neomycin) components. It indicates that the ingredients are effective against a wide range of susceptible fungal and bacterial pathogens.

Q: Are there known concerns about Candiderm and alcohol consumption?

Official regulatory documents primarily focus on drug-drug interactions. Interactions between topically applied Candiderm and alcohol consumption are not typically listed in the official labeling.

Q: What does regulatory labeling say about the potential for systemic absorption of Candiderm?

Regulatory labeling states that the extent of percutaneous (systemic) absorption is determined by several factors. These factors include the size of the treated area, the integrity of the skin barrier, and the use of occlusive dressings.

How should Candiderm be stored and disposed of?

How to Store and Dispose of Candiderm Cream

Official regulatory guidelines mandate specific conditions for storing and disposing of Candiderm Cream to ensure product stability and safety. The medicine must be stored at a temperature below 30 C and must not be frozen. It is required to protect the cream away from direct sunlight and moisture and to keep the container tightly closed.

Required Handling and Safety

Requirement Official Instruction
Temperature & Environment Store below 30 C; Do not freeze; Protect from light and moisture.
Child Safety Keep out of the sight and reach of children.
Disposal Dispose of unused or expired product to ensure it is not consumed by pets or others.

All medicine must be kept out of the sight and reach of children and the unused product should be properly disposed of following local regulatory guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Candiderm found in:

A-Z Index: